Thomas H - Search Results

1

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.

Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Matheson EC, et al. Among authors: thomas h. Haematologica. 2019 Sep;104(9):1804-1811. doi: 10.3324/haematol.2017.185975. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655370 Free PMC article.

2

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.

Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Noble RA, et al. Among authors: thomas h. Haematologica. 2017 Jul;102(7):1247-1257. doi: 10.3324/haematol.2016.163030. Epub 2017 Apr 6. Haematologica. 2017. PMID: 28385782 Free PMC article.

3

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA. Chen L, et al. Int J Cancer. 2019 Jun 15;144(12):3146-3159. doi: 10.1002/ijc.32058. Epub 2019 Jan 9. Int J Cancer. 2019. PMID: 30536898 Free PMC article.

4

The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.

Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. Haagensen EJ, et al. PLoS One. 2013 Dec 10;8(12):e81763. doi: 10.1371/journal.pone.0081763. eCollection 2013. PLoS One. 2013. PMID: 24339963 Free PMC article.

5

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.

Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Haagensen EJ, et al. Eur J Cancer. 2016 Mar;56:69-76. doi: 10.1016/j.ejca.2015.12.012. Epub 2016 Jan 25. Eur J Cancer. 2016. PMID: 26820797

6

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.

Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Haagensen EJ, et al. Cancer Chemother Pharmacol. 2016 Dec;78(6):1269-1281. doi: 10.1007/s00280-016-3186-4. Epub 2016 Nov 11. Cancer Chemother Pharmacol. 2016. PMID: 27837257 Free PMC article.

7

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Hill CR, Jamieson D, Thomas HD, Brown CD, Boddy AV, Veal GJ. Hill CR, et al. Biochem Pharmacol. 2013 Jan 1;85(1):29-37. doi: 10.1016/j.bcp.2012.10.004. Epub 2012 Oct 11. Biochem Pharmacol. 2013. PMID: 23063411 Free PMC article.

8

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.

Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. Almeida GS, et al. NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3736. Epub 2017 May 22. NMR Biomed. 2017. PMID: 28543772

9

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.

Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Thomas HD, et al. Mol Cancer Ther. 2009 Jul;8(7):1828-37. doi: 10.1158/1535-7163.MCT-08-1208. Epub 2009 Jun 9. Mol Cancer Ther. 2009. PMID: 19509274

10

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ. Zhao Y, et al. Cancer Res. 2006 May 15;66(10):5354-62. doi: 10.1158/0008-5472.CAN-05-4275. Cancer Res. 2006. PMID: 16707462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,228 results

Search Page

Filters